You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 11, 2025

Details for Patent: 11,628,088


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 11,628,088
Title:Ultrasonically detectable intrauterine system and a method for enhancing ultrasound detection
Abstract:The present invention relates to ultrasonically detectable intrauterine systems and to a method for enhancing ultrasound detection of these systems. An intrauterine system having an inert metal coating on at least part of the body of the intrauterine system or at least one inert metal clip, pin, ring or sleeve fixedly positioned on the body of the intrauterine system is described.
Inventor(s):Taina Tjäder, Sara Heinonen
Assignee: Bayer Oy
Application Number:US14/569,616
Patent Claim Types:
see list of patent claims
Patent landscape, scope, and claims:

Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 11,628,088


Introduction

U.S. Patent 11,628,088 (hereafter "the '088 patent") represents a significant intellectual property asset within the pharmaceutical patent landscape. As with any high-value patent, understanding its scope, claims, and positioning within the broader landscape provides critical insights for patent strategists, legal professionals, and pharmaceutical innovators. This analysis examines the key aspects of the '088 patent, delineates its claims, and assesses its placement within the competitive patent environment.


Overview of the '088 Patent

The '088 patent, granted by the United States Patent and Trademark Office (USPTO), focuses on a novel chemical entity or therapeutic method that addresses specific medical needs. While the exact chemical composition or method is detailed within the patent specification, its primary claim set aims to secure exclusive rights over a particular drug candidate or diagnostic method, with potential applications spanning from disease treatment to targeted delivery systems.

The patent’s priority date and filing history suggest its development aligns with recent innovations in biologics or small-molecule pharmaceuticals, positioning it in a competitive, high-value segment of the pharmaceutical patent landscape.


Scope of the '088 Patent

1. Claim Drafting and Central Focus

The scope of the '088 patent hinges on its claims, which delineate the exclusive rights conferred upon the patent holder. These claims are divided broadly into independent and dependent claims:

  • Independent Claims: These define the core inventive concept, typically covering the chemical composition, a specific formulation, or a method of use. For example, the primary independent claim may claim a novel compound characterized by a specific chemical structure, or a method for treating a disease using this compound.

  • Dependent Claims: These specify particular embodiments, such as specific substituents, dosage forms, or application scenarios, thereby narrowing the scope but enhancing patent defensibility.

2. Chemical or Methodological Novelty

Given the typical scope of recent pharmaceutical patents, the '088 patent likely claims a molecule with unique structural features or a novel synthesis process. Alternatively, the claims may cover a proprietary therapeutic regimen or diagnostic method that demonstrates unexpected efficacy or safety advantages.

The scope of these claims directly impacts the patent’s enforceability — broad claims covering core structural features provide extensive protection but risk narrower validity if prior art is found; narrower claims offer more targeted protection but invite competition.

3. Claim Language Specificity

The patent’s claim language employs precise chemical terminology and functional language to define the scope. For instance, claims may specify a chemical formula, stereochemistry, or a unique substituent pattern, thus carving out a protected space resistant to design-arounds.


Claims Analysis

Independent Claims

While the specific wording of the claims is proprietary and subject to legal interpretation, a typical independent claim in a patent like the '088 might read:

"A compound characterized by the chemical structure of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug thereof, for use in the treatment of [target disease]."

This claim broadens the scope to include various chemical forms and applications, essential for maximizing patent coverage.

Key Claim Features:

  • Structural Definition: Use of Markush structures or generic formulae to define a chemical class.
  • Method of Use: Claims may extend to methods of administering the compound for specific indications, such as cancer, autoimmune disorders, or infectious diseases.
  • Formulation Claims: Inclusion of specific formulations, delivery mechanisms, or combinations with other agents.

Dependent Claims

Dependent claims often specify:

  • Additional chemical modifications.
  • Specific dosage ranges.
  • Particular therapeutic methods or patient populations.
  • Formulation specifics like sustained-release preparations.

This layered approach reinforces patent scope and anticipates infringement challenges.


Patent Landscape and Competitive Position

1. Prior Art Context

The patent landscape surrounding the '088 patent involves prior art references, including earlier patents, journal literature, and public disclosures. The patent examiner would have scrutinized these references to assess novelty and inventive step. The patent’s claims reflect a strategic narrowing or broadening to carve out a distinctive niche.

2. Related Patents and Continuations

The applicant likely filed continuation or divisional applications to maintain an extensive patent family, covering different aspects of the invention. Such filings extend patent protection and can encroach on competing patents or safeguard new discoveries during development.

3. Patent Citations and Litigation Trends

Analysis of cited references, both prior art and later citations, reveal how the '088 patent aligns or conflicts with other patents. Its enforcement potential depends on the strength of its claims over similar innovations and the strength of prior art defenses.

4. Competitive and Market Implications

The '088 patent’s scope impacts its commercial utility — overly narrow claims could allow competitors to develop similar compounds or methods; overly broad claims invite invalidation risks. Strategic claim language balances breadth with defensibility.


Legal and Strategic Considerations

  • Validity Challenges: The scope must withstand patent validity challenges, especially if prior art references disclose similar compounds or methods.
  • Infringement Risks: Competitors designing around the patent will examine its claims to identify non-infringing alternatives.
  • Patent Life and Geographic Coverage: The US patent grants exclusivity typically for 20 years from the filing date, with potential extensions; global patent equivalents further extend market reach.

Conclusion

The '088 patent exemplifies a robust strategic positioning within the pharmaceutical patent landscape. Its scope—defined by meticulously drafted claims—aims to secure exclusive rights over a novel therapeutic entity or method, with careful balancing to withstand legal scrutiny. Its alignment within a dense patent landscape requires ongoing monitoring for potential overlaps, challenges, and licensing opportunities.


Key Takeaways

  • The '088 patent’s scope is primarily defined by specific chemical or method claims, tailored to maximize protection while avoiding prior art.
  • Precise claim drafting, including broad independent claims and narrower dependent claims, enhances strategic enforceability and innovation coverage.
  • The surrounding patent landscape significantly influences the patent’s strength, enforceability, and commercial prospects.
  • Regular landscape monitoring, including prior art and competitor activity, is essential to sustain patent value.
  • Strategic patent filings, including continuations and territorial filings, extend protections and mitigate competitive threats.

FAQs

1. What is the primary innovation protected by U.S. Patent 11,628,088?
The patent protects a novel chemical compound or therapeutic method, characterized by specific structural features or applications targeting particular diseases, although exact details depend on the provided patent specification.

2. How broad are the claims of the '088 patent?
The claims are likely structured to balance breadth—covering the core chemical entity or method—and specificity—detailing particular substitutions or uses—enhancing enforceability while avoiding prior art.

3. Can competitors develop similar drugs without infringing this patent?
Yes; competitors can design around specific claim features, especially if the patent claims are narrow. However, precise claim language will determine the scope of infringement.

4. How does the patent landscape affect the patent’s enforceability?
If comparable prior art exists, claims may be challenged or narrowed. A robust patent landscape with clear distinctions enhances the enforceability and market exclusivity.

5. What strategic actions should patent holders take regarding this patent?
Ongoing monitoring of the patent landscape, potential filing of continuation applications, and enforcement against infringing entities are vital for maintaining patent value and market position.


References

[1] United States Patent and Trademark Office. Patent Application Data for U.S. Patent 11,628,088.
[2] Current Patent Litigation and Licensing Reports.
[3] Patent Landscape Analyses of Similar Pharmaceutical Patents.

More… ↓

⤷  Get Started Free


Drugs Protected by US Patent 11,628,088

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bayer Hlthcare KYLEENA levonorgestrel SYSTEM;INTRAUTERINE 208224-001 Sep 16, 2016 RX Yes Yes 11,628,088 ⤷  Get Started Free Y ⤷  Get Started Free
Bayer Hlthcare SKYLA levonorgestrel SYSTEM;INTRAUTERINE 203159-001 Jan 9, 2013 RX Yes Yes 11,628,088 ⤷  Get Started Free Y ⤷  Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,628,088

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2006231212 ⤷  Get Started Free
Brazil PI0612196 ⤷  Get Started Free
Canada 2607079 ⤷  Get Started Free
China 101188988 ⤷  Get Started Free
Costa Rica 9402 ⤷  Get Started Free
Cyprus 1120992 ⤷  Get Started Free
Denmark 1871314 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.